Theratechnologies Inc T.TH

Akero

[Trogarzon]

Akero got a Pause moment yesterday with it's p2 results, chpeed in half.  Maybe this gives good old pulsative slowly but shurly Egrifta a chance to attract attention once again.

[Joemare]

"Tesamorelin suppressed key angiogenic, fibrogenic, and pro-inflammatory mediators. CSF1, a regulator of monocyte recruitment and activation, may serve as an innovative therapeutic target for NAFLD in HIV" Tesamorelin comes in where AKRO failed today??  Use Grinspoon to take this to a combo approch/partnership........

[Mannequin]

Why does TH only have something for HIV and not all people with a NASH risk?  What is the difference?  If it has something to offer HIV patients, why not someone without HIV?

[scarlet1967]

So far (36 weeks results) their anti fibrotic drug didn't show statistically significant resolution of fibrosis on the NASH resolution the drug had better results. Also due to adverse effects there were some discontinuations. One has to wonder even with the drop today how their market cap can be justified or/and how the market doesn't ascribe any Value to THTX's NASH asset? 

[LouisW]

I remember that Tesamorelin also barely alleviated fibrosis only to improve Fat accumulation and concomitant NASH.

[Trogarzon]

Going done on dismal volume by association from stupida algos or just stupido person.  Different mechanism of action, should benefit THTX's Nash approach.  Not priced in by any metric.  Just idiotic markets.

[Joemare]

Yes, important safety issues with their drug.   Not significance + safety = major drop in value. Need to push for combo treatment.

[Trogarzon]

Need to push the C-suite over the cliff.... and get Bellinni.

[Trogarzon]

It honestly time something material happens overthere. No mews on recruitement yet... friggin 2 months and still nothing... slow walking it is an understatement.

[Trogarzon]

It's going to be one year anniversary of the Pause that crashed the valuation of Thera.  A pause for something that was considered to be ignored in the stock price back at 3$ (now 12$).  Since then it's trading fourfold lower than that on nothing more, nothing less.  If we were at 12$ now it would be adequate, but not 2.67$.. thats 66 cents cdn.  It is unacceptable and

[PWIB123]

I'm choosing to be patient and accept the fact that they are being more selective with patients and it might take longer this time.  Unfortunately, it doesn't sound like we'll know much until next year, but I'm trusting it will be worth the wait.  

[Trogarzon]

Maybe they could put money in their worthless peice of paper in the mean time if they have an ounce of confidence in their company.